HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jeffrey L. Port Robert J. Korst Paul C. Lee Nasser K. Altorki Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Port, J. L. Articles by Altorki, N. K. Search for Related Content PubMed PubMed Citation Articles by Port, J. L. Articles by Altorki, N. K. Related Collections Lung - cancer

Ann Thorac Surg 2005;79:1686-1690
© 2005 The Society of Thoracic Surgeons

---

Original articles: General thoracic

Surgical Resection for Residual N₂ Disease After Induction Chemotherapy

Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, New York

Accepted for publication October 26, 2004.

^_* Address reprint requests to Dr Altorki, Department of Cardiothoracic Surgery, Suite M404, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021 (E-mail: nkaltork{at}med.cornell.edu).

Presented at the Poster Session of the Fortieth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 26–28, 2004.

BACKGROUND: Induction therapy is a common treatment modality for patients with stage IIIA non-small cell lung cancer (NSCLC). Although mediastinal nodal downstaging after induction therapy is generally considered a favorable prognostic feature, the benefit of resection in the presence of residual N₂ disease is controversial. In this study we analyzed our experience with resection after induction chemotherapy in patients with residual N₂ disease to more precisely define the role of surgical resection in this group of patients.

METHODS: In this retrospective analysis, we reviewed the records of 78 patients with N₂ disease who received induction therapy with preoperative intent between 1990 and 2003. All patients had potentially resectable disease. Survival analysis was performed using the Kaplan-Meier method. A Cox proportional hazards regression model was used to evaluate multiple prognostic factors.

RESULTS: There were 78 patients (39 men) with a median age of 64 years. Sixty had nonsquamous histology. Resection was performed in 52 patients (47 R₀). Hospital mortality was 1.9%. A complete pathologic response occurred in 2 of 52 (3.8%) patients and 19 of 52 (36%) patients had no residual N₂ disease. Overall 5-year survival for resected patients was 23%. Overall 5-year survival was 30% for N₀-N₁ patients and 19% for those with residual N₂ disease. Multivariable analysis identified clinical response to therapy (p = 0.0007) and histology (p = 0.01), but not residual N₂ disease (p = 0.65), as important prognostic variables.

CONCLUSIONS: Surgical resection may be a viable option for patients with residual N₂ disease after induction chemotherapy, provided an R₀ resection can be performed.

This article has been cited by other articles:

				H. Decaluwe, P. De Leyn, J. Vansteenkiste, C. Dooms, D. Van Raemdonck, P. Nafteux, W. Coosemans, and T. Lerut Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival Eur. J. Cardiothorac. Surg., September 1, 2009; 36(3): 433 - 439. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, E. Gyllstedt, A. Pikwer, and P. Jonsson Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Ann. Thorac. Surg., August 1, 2008; 86(2): 376 - 382. [Abstract] [Full Text] [PDF]

				C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185. [Abstract] [Full Text] [PDF]

				R. J. Battafarano Optimal management of patients with non-small cell lung cancer with ipsilateral mediastinal lymph node metastases J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1227 - 1228. [Full Text] [PDF]